Close

AstraZeneca begins Phase III trial of Covid-19 vaccine in US

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Insulated Pallet Protection in Temperature-Sensitive Pharmaceutical Shipping

In the pharmaceutical industry, products frequently require very specific...

Litmys and PharmaACE Establish Strategic Partnership for Market Projections

Life sciences consulting firms Litmys and PharmaACE have officially...

Blackstone Provides Up to $1.5 Billion for Pfizer’s Obesity Drug Candidate

Private equity firm Blackstone Life Sciences has agreed to...
- Advertisement -

AstraZeneca has expanded the clinical development of its potential Covid-19 vaccine candidate AZD1222 in the US, by initiating a Phase 3 clinical trial, dubbed D8110C00001.

The late-stage clinical trial is aimed at evaluating the safety, efficacy and immunogenicity of the AZD1222 vaccine in up to 30,000 adults, aged 18 years or above, across nearly 100 trial centres in and outside the US.

Developed by the University of Oxford and its spin-out company, Vaccitech, AZD1222 leverages a replication-deficient chimpanzee viral vector and contains the genetic material of the SARS-CoV-2 virus spike protein, to induce immune response against the virus.

The company is conducting the clinical trial, with funding from the Biomedical Advanced Development Authority (BARDA), and the National Institute of Allergy and Infectious Diseases (NIAID).

AstraZeneca biopharmaceuticals R&D executive vice president Mene Pangalos said: “We are pleased that AZD1222 demonstrated safety and immunogenicity across all adult age groups and are proud to be collaborating with BARDA and NIAID to accelerate the development of this vaccine.

“Should clinical trials demonstrate the vaccine protects against COVID-19 disease and is approved for use, we will work hard to make it globally available in a fair and equitable manner as rapidly as possible.”

D8110C00001 will enrol subjects who are at elevated risk of SARS-CoV-2 infection

The D8110C00001 trial is planned to enrol subjects from various racial, ethnic and geographic groups who are at elevated risk of SARS-CoV-2 infection, and randomise them in a 2:1 ratio, either to receive two doses of AZD1222 or saline control, in a span of four weeks.

The clinical trial will enrol patients outside the US, including in Peru and Chile, based on predicted transmission rates of the virus, said the company.

AZD1222’s developmentis being carried out across the world, with late-stage clinical trials underway in the UK, Brazil and South Africa and clinical trials to begin in Japan and Russia.

The clinical trials across the global, including the current US Phase 3 clinical trial, are expected to study up to 50,000 participants across the world.

Interim results from the Phase 1/2 COV001 trial, unveiled in July 2020, demonstrated that AZD1222 was well tolerated, and induced strong immune responses against the SARS-CoV-2 virus in all evaluated participants.

The company has signed several supply agreements with various countries including Russia, South Korea, Japan, China, Latin America and Brazil, to ensure the global supply of its Covid-19 vaccine.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Insulated Pallet Protection in Temperature-Sensitive Pharmaceutical Shipping

In the pharmaceutical industry, products frequently require very specific...

Litmys and PharmaACE Establish Strategic Partnership for Market Projections

Life sciences consulting firms Litmys and PharmaACE have officially...

Blackstone Provides Up to $1.5 Billion for Pfizer’s Obesity Drug Candidate

Private equity firm Blackstone Life Sciences has agreed to...

How Biopharmaceutical Research Is Shaping the Future of Cancer Treatment

Cancer is no longer viewed solely as a clinical...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »